PLoS One, 2022, 17(8):e0273340

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study

The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone.

Bryushkova EA, Skatova VD, Mutovina ZY, Zagrebneva AI, Fomina DS, Kruglova TS, Akopyan AA, Strazhesko ID, Lukyanov SA, Tkacheva ON, Lysenko MA, Chudakov DM

Department of Genomics and Postgenomic Technologies, Department of Genomics of Adaptive Immunity, Laboratory of immunosequencing methods, Group of Structural Organization of T-cell Immunity

: 10.1371/journal.pone.0273340
Scopus: 2-s2.0-85136951093
: 36001576
IBCH: 10160
Ссылка на статью в журнале: https://dx.plos.org/10.1371/journal.pone.0273340
Кол-во цитирований на 04.2025: 12
Данные статьи проверены модераторами 2022-09-02

Список научных проектов, где отмечена публикация

  1. 075-15-2020-807. . Сommercial.